Table 2 KEGG signaling pathways modulated by predicted miR-101-3p targets downregulated experimentally in HCT116 cells
Pathway and Genes | Target Count | % | P-Value | Benjamini |
|---|---|---|---|---|
Wnt signaling pathway CXXC4, CAMK2G, FZD4, FZD6, NLK, PLCB1, RAC1 | 7 | 3,6 | 2,1E-3 | 2,7E-1 |
Melanogenesis GNAI3, ADCY6, CAMK2G, FZD4, FZD6, PLCB1 | 6 | 3,1 | 2,7E-3 | 1,8E-1 |
Pathways in cancer CEBPA, GNAI3, ADCY6, FZD4, FZD6, ITGA3, PAX8, PLCB1, RAC1, RXRB, TCEB1 | 11 | 5,7 | 4,3E-3 | 1,9E-1 |
Sphingolipid signaling pathway GNAI3, CERS2, CERS6, PLCB1, RAC1, SGPL1 | 6 | 3,1 | 6,0E-3 | 2,0E-1 |
Ubiquitin mediated proteolysis MGRN1, TCEB1, UBE2A, UBE2D1, UBE2D3, UBE2Q1 | 6 | 3,1 | 1,0E-2 | 2,6E-1 |
Phosphatidylinositol signaling system CDS2, MTMR2, PIP5K1C, PLCB1, TMEM55A | 5 | 2,6 | 1,5E-2 | 3,1E-1 |
Transcriptional misregulation in cancer CEBPA, DOT1L, PAX8, RXRB, SLC45A3, MYCN | 6 | 3,1 | 2,3E-2 | 3,9E-1 |
Gastric acid secretion GNAI3, ADCY6, CAMK2G, PLCB1 | 4 | 2,1 | 3,3E-2 | 4,7E-1 |
cAMP signaling pathway GNAI3, SOX9, ADCY6, CAMK2G, PDE4A, RAC1 | 6 | 3,1 | 4,2E-2 | 5,1E-1 |
Proteoglycans in cancer GAB1, CAMK2G, CAV3, FZD4, FZD6, RAC1 | 6 | 3,1 | 4,4E-2 | 4,9E-1 |
Insulin secretion ADCY6, CAMK2G, PLCB1, KCNN3 | 4 | 2,1 | 4,9E-2 | 4,9E-1 |
Gap junction GNAI3, ADCY6, GJA1, PLCB1 | 4 | 2,1 | 5,3E-2 | 4,9E-1 |
Circadian entrainment GNAI3, ADCY6, CAMK2G, PLCB1 | 4 | 2,1 | 6,4E-2 | 5,3E-1 |
Inflammatory mediator regulation of TRP channels ASIC1, ADCY6, CAMK2G, PLCB1 | 4 | 2,1 | 6,9E-2 | 5,3E-1 |
Sphingolipid metabolism CERS2, CERS6, SGPL1 | 3 | 1,6 | 7,6E-2 | 5,4E-1 |
Cholinergic synapse GNAI3, ADCY6, CAMK2G, PLCB1 | 4 | 2,1 | 9,2E-2 | 5,9E-1 |